Leukemia News

The FDA granted fast track designation to eryaspase for treatment of patients with acute lymphoblastic leukemia who developed hypersensitivity reactions to E. coli-derived pegylated asparaginase.

Eprenetapopt with azacitidine exhibited encouraging activity as posttransplant maintenance therapy for patients with TP53-mutant myelodysplastic syndrome and acute myeloid leukemia, topline data released by the agent’s manufacturer showed.

Ficlatuzumab plus single-agent chemotherapy showed encouraging efficacy and appeared safe among patients with relapsed or refractory acute myeloid leukemia, according to phase 1 study results published in Blood Cancer Discovery.

The COVID-19 pandemic has underscored the importance of vaccination, both in terms of protecting individuals from infection and eradicating threats to public health.

CD19-directed chimeric antigen receptor T-cell therapies have produced unprecedented response rates among patients with advanced hematologic malignancies, yet many patients who respond to this therapy experience disease relapse.

ASH will present honorific awards to several hematologists during this year’s ASH Annual Meeting, scheduled for Dec. 11-14.

Sarah K. Tasian, MD, has been appointed chief of the section of hematologic malignancies within the division of oncology at Children’s Hospital of Philadelphia.

In this video, John C. Byrd, MD, a professor at The Ohio State University, discussed the study he presented at ASCO21 that showed progression-free survival rates were equal among patients with CML treated with acalabrutinib vs. ibrutinib.

In this video, John C. Byrd, MD, a professor at The Ohio State University, discussed the results of a phase 2 study that evaluated a new CAR T-cell therapy for adult patients with ALL.

In this video, John C. Byrd, MD, a professor at The Ohio State University, discussed a pair of abstracts that looked at the use of ponatinib for Philadelphia chromosome positive ALL and resistant CML. One study looked at dose optimization of ponatinib for patients with CML, which indicated that starting treatment with a higher dose and then titrating down was effective.